Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Sovaldi Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Sovaldi (sofosbuvir) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and exception review for Sovaldi used to treat specified chronic or recurrent hepatitis C virus infections in adults and pediatric patients who meet the required clinical, prescriber, regimen, fibrosis, cirrhosis, and treatment-duration criteria.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicySovaldi (sofosbuvir) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit prior authorization requests that document the covered indication, required combination regimen, and treatment duration.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1, 2, 3HCV genotypes covered
    12 or 24 wkTreatment duration
    ≥2Fibrosis threshold
    ≥12 yr or 35 kgPediatric threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Archived
    Policy status

    Covered Indications and Exclusions

    Adult Chronic HCV Genotype 1 — 12 Weeks

    Covered for 12 weeks when ALL of the following are met:

    ALL of the following

    • The patient is ≥ 18 years of age.
    • Sovaldi is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • The patient has a fibrosis score of ≥ 2.
    • ONE of the following treatment regimens applies:

      • ALL of the following

        • Sovaldi will be prescribed in combination with Olysio (simeprevir capsules).
        • The patient does not have cirrhosis.

          Patients with cirrhosis receiving Sovaldi in combination with Olysio are addressed under the 24-week criteria.

      • ALL of the following

        • Sovaldi will be prescribed in combination with Daklinza (daclatasvir tablets).
        • ONE of the following cirrhosis conditions applies:

          • The patient does not have cirrhosis.
          • The patient has compensated cirrhosis (Child-Pugh A).
          • ALL of the following

            • The patient has decompensated cirrhosis (Child-Pugh B or C).
            • Sovaldi will be prescribed in combination with Daklinza and ribavirin.

    Adult Chronic HCV Genotype 1 With Cirrhosis — 24 Weeks

    Covered for 24 weeks when ALL of the following are met:

    ALL of the following

    • The patient is ≥ 18 years of age.
    • Sovaldi is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • The patient has a fibrosis score of ≥ 2.
    • Sovaldi will be prescribed in combination with Olysio (simeprevir capsules).
    • The patient has cirrhosis.

    Pediatric Chronic HCV Genotype 2 — 12 Weeks

    Covered for 12 weeks when ALL of the following are met:

    ALL of the following

    • The patient is ≥ 12 years of age or weighs ≥ 35 kg.
    • Sovaldi is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • Sovaldi will be prescribed in combination with ribavirin.
    • The patient has a fibrosis score of ≥ 2.
    • The patient does not have decompensated cirrhosis (Child-Pugh B or C).

      Coverage is provided for patients without cirrhosis or with compensated (Child-Pugh A) cirrhosis.

    Pediatric Chronic HCV Genotype 3 — 24 Weeks

    Covered for 24 weeks when ALL of the following are met:

    ALL of the following

    • The patient is ≥ 12 years of age or weighs ≥ 35 kg.
    • Sovaldi is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • The patient has a fibrosis score of ≥ 2.
    • Sovaldi will be prescribed in combination with ribavirin.
    • The patient does not have decompensated cirrhosis (Child-Pugh B or C).

      Coverage is provided for patients without cirrhosis or with compensated (Child-Pugh A) cirrhosis.

    Adult Chronic HCV Genotype 3 — 12 Weeks

    Covered for 12 weeks when ALL of the following are met:

    ALL of the following

    • The patient is ≥ 18 years of age.
    • Sovaldi is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • The patient has a fibrosis score of ≥ 2.
    • Sovaldi is prescribed in combination with Daklinza (daclatasvir tablets).
    • ONE of the following conditions applies:

      • The patient does not have cirrhosis.

    Recurrent HCV After Liver Transplantation — Genotypes 1, 2, and 3 Adults

    Covered for 12 weeks when ALL of the applicable criteria are met. For a patient already started on Sovaldi for an approved indication or condition, approve the remaining duration needed to complete the applicable course.

    ALL of the following

    • The patient is ≥ 18 years of age.
    • The patient has recurrent HCV after liver transplantation.
    • Sovaldi is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician affiliated with a transplant center.
    • ONE of the following genotype-specific regimens applies:

      • ALL of the following

        • The patient has genotype 1 recurrent HCV.

    Sovaldi is not approved for the following uses or situations:

    Combination use with direct-acting antivirals (DAAs) other than Daklinza, Olysio, or ribavirin.

    Life expectancy of less than 12 months due to non-liver-related comorbidities.

    Monotherapy with Sovaldi.

    Pediatric patients younger than 12 years of age or weighing less than 35 kg.

    Clinical Thresholds and Eligibility Parameters

    Fibrosis score
    Required thresholdFibrosis score ≥ 2
    Applies toCovered chronic HCV treatment criteria
    Clinical requirementThe patient must have a fibrosis score of at least 2
    Pediatric age or weight
    Age requirementAt least 12 years
    Weight alternativeAt least 35 kg
    Eligibility ruleThe patient must meet either the age or weight threshold

    Authorization and Request Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Sovaldi. Approval is limited to the qualifying FDA-approved HCV indications or the supported-evidence pathway for recurrent HCV after liver transplantation, with the regimen and duration specified below.

    • Chronic HCV genotype 1 in adults: approved combinations and 12- or 24-week duration based on cirrhosis status.
    • Chronic HCV genotype 2 or 3 in pediatric patients and genotype 3 in adults: approved age/weight, fibrosis, cirrhosis, regimen, and duration criteria must be met.
    • Recurrent HCV genotypes 1, 2, or 3 after liver transplantation in adults: transplant-center specialist involvement and specified combination therapy are required.
    Prior Authorization

    Continuation of an Initiated Course

    If the patient has already started Sovaldi, request authorization for the remaining portion of a covered course when the patient meets an approved indication or supported-evidence pathway. The approved remaining duration equals the applicable total course duration minus the treatment already received.

    Therapy Overview

    Sovaldi (sofosbuvir) is an HCV nucleotide analog NS5B polymerase inhibitor used as part of combination antiviral treatment rather than as monotherapy. This policy addresses chronic hepatitis C virus genotypes 1, 2, and 3, including selected adult, pediatric, and recurrent post-liver-transplant infections. Coverage is dependent on the applicable fibrosis and cirrhosis status, specialist involvement, required companion antiviral regimen, and approved treatment duration.

    Clinical Definitions

    Compensated cirrhosis
    ClassificationChild-Pugh A
    DefinitionCirrhosis without decompensation
    Coverage contextCovered criteria include patients without cirrhosis or with compensated Child-Pugh A cirrhosis when the applicable regimen requirements are met
    Decompensated cirrhosis
    ClassificationChild-Pugh B or C
    DefinitionCirrhosis classified as Child-Pugh B or C
    Coverage contextPediatric genotype 2 and 3 criteria exclude decompensated cirrhosis; certain adult regimens require ribavirin when it is present

    Initial Therapy Decision Paths

    Genotype 1 Adult Initial Therapy

    Approve the applicable duration when all required adult, specialist, fibrosis, regimen, and cirrhosis criteria are met.

    Genotype 1 adult treatment duration

    • 12-week Olysio regimen: Patient is at least 18 years old, has a fibrosis score of at least 2, and Sovaldi is prescribed by or in consultation with an eligible specialist in combination with Olysio; the patient does not have cirrhosis12 weeks
    • 12-week Daklinza regimen: Patient is at least 18 years old, has a fibrosis score of at least 2, and Sovaldi is prescribed by or in consultation with an eligible specialist in combination with Daklinza; the patient has no cirrhosis or compensated cirrhosis, or has decompensated cirrhosis with ribavirin added12 weeks

    Continuation of Existing Treatment

    Patient Already Started on Sovaldi

    Patients already started on Sovaldi may be approved to complete the applicable covered course.

    Continuation of an approved course

    • Covered indication: The initial indication meets a covered approval criterion
    • Remaining course: Authorize only the amount needed to complete the applicable total durationRemaining weeks

    Authorized Treatment Duration

    Sovaldi quantity limits
    Standard course12 weeks for covered indications specified for a 12-week duration
    Extended course24 weeks for covered indications specified for a 24-week duration
    Continuation limitAuthorize only the remaining time needed to complete the applicable approved course
    Policy Summary
    PayerVentura County Health Care Plan
    PolicySovaldi (sofosbuvir) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit prior authorization requests that document the covered indication, required combination regimen, and treatment duration.
    SourceLink
    On This Page
    Covered Indications and ExclusionsClinical Thresholds and Eligibility ParametersAuthorization and Request RequirementsTherapy OverviewClinical DefinitionsInitial Therapy Decision PathsContinuation of Existing TreatmentAuthorized Treatment Duration
  1. ALL of the following

    • The patient has cirrhosis, including compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis.
    • Daklinza and Sovaldi will be prescribed in combination with ribavirin.
  2. ANY of the following

    • Sovaldi is prescribed in combination with Olysio.
    • Sovaldi is prescribed in combination with Daklinza and ribavirin.
  3. ALL of the following

    • The patient has genotype 2 recurrent HCV.
    • Sovaldi is prescribed in combination with Daklinza and ribavirin.
  4. ALL of the following

    • The patient has genotype 3 recurrent HCV.
    • Sovaldi is prescribed in combination with Daklinza and ribavirin.
  5. Adult age
    Minimum ageAt least 18 years
    Applies toAdult chronic HCV treatment criteria
    Eligibility ruleThe patient must be 18 years of age or older
    Life expectancy exclusion
    Exclusion thresholdLife expectancy less than 12 months
    CauseNon-liver-related comorbidities
    Coverage statusSovaldi is not approved when this exclusion applies
    • Example: a patient approved for a 12-week course who has completed 3 weeks may be approved for the remaining 9 weeks.
    • The completed and remaining treatment duration should be documented in the request.
    Documentation Required

    Clinical Information Supporting Authorization

    Submit clinical documentation sufficient to verify the indication, eligibility, regimen, and requested duration. Documentation should support the patient’s genotype, age or weight, fibrosis and cirrhosis status, prescriber qualifications, transplant history when applicable, and all drugs included in the regimen.

    • HCV genotype and patient age; for pediatric requests, document age and weight.
    • Fibrosis score of ≥ 2 and cirrhosis status, including Child-Pugh class when applicable.
    • Prescriber identity and specialty; recurrent post-transplant cases require a qualifying specialist affiliated with a transplant center.
    • Requested regimen, including Daklinza, Olysio, and/or ribavirin as applicable.
    • Requested treatment duration and, for continuation requests, the number of weeks already completed and remaining.

    Unsupported block type: denial_risk

    Denial Risk

    Failure to Meet Clinical Criteria

    Authorization may be denied when the patient does not meet all applicable clinical criteria for the requested indication. Denial conditions include failure to establish eligibility, an appropriate prescriber, required fibrosis or genotype criteria, permitted cirrhosis status, an approved regimen, or the specified treatment duration.

    • Patient does not meet the applicable age or weight requirement, including adult versus pediatric criteria.
    • Sovaldi is not prescribed by or in consultation with a qualifying gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician; post-transplant requests also lack required transplant-center affiliation.
    • Fibrosis score is below 2 or is not documented.
    • HCV genotype does not match a covered pathway, or recurrent post-liver-transplant HCV is not established when that pathway is requested.
    • Cirrhosis or Child-Pugh status is inconsistent with the requested indication, such as decompensated cirrhosis where the criteria require no decompensation or compensated cirrhosis.
    • Required combination therapy is absent or incorrect, including Daklinza, Olysio, or ribavirin requirements.
    • Requested duration does not match the applicable 12- or 24-week criteria or exceeds the remaining duration of an eligible initiated course.
    Fibrosis score
    DefinitionA measure or score of liver fibrosis
    Covered thresholdFibrosis score ≥ 2
    RequirementMost covered treatment criteria require a score of at least 2
    24-week Olysio regimen: Patient is at least 18 years old, has a fibrosis score of at least 2, and Sovaldi is prescribed by or in consultation with an eligible specialist in combination with Olysio; the patient has cirrhosis24 weeks

    Pediatric Genotype 2 or 3 Initial Therapy

    Approve the applicable duration when all required pediatric, specialist, fibrosis, regimen, and cirrhosis criteria are met.

    Pediatric genotype 2 or 3 initial therapy

    • Genotype 2: Patient is at least 12 years old or weighs at least 35 kg; Sovaldi is prescribed by or in consultation with an eligible specialist; fibrosis score is at least 2; Sovaldi is prescribed with ribavirin; and the patient does not have decompensated cirrhosis12 weeks

      Coverage includes no cirrhosis or compensated Child-Pugh A cirrhosis

    • Genotype 3: Patient is at least 12 years old or weighs at least 35 kg; Sovaldi is prescribed by or in consultation with an eligible specialist; fibrosis score is at least 2; Sovaldi is prescribed with ribavirin; and the patient does not have decompensated cirrhosis24 weeks

      Coverage includes no cirrhosis or compensated Child-Pugh A cirrhosis

    Adult Genotype 3 Initial Therapy

    Approve for 12 weeks when all criteria are met.

    Adult genotype 3 initial therapy

    • Age: Patient is at least 18 years old≥18 years
    • Fibrosis score is at least 2≥2
    • Specialist prescriber: Sovaldi is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician

    Recurrent Post-Liver-Transplant HCV

    Approve for 12 weeks when all criteria are met.

    Post-transplant recurrent HCV initial therapy

    • Adult recurrent HCV: Patient is at least 18 years old and has recurrent HCV after liver transplantation≥18 years
    • Eligible specialist: Sovaldi is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician affiliated with a transplant center
    • Required genotype-specific combination

      • Genotype 1 recurrent HCV treated with Sovaldi plus Olysio, or Sovaldi plus Daklinza and ribavirin12 weeks
      • Genotype 2 or 3 recurrent HCV treated with Sovaldi plus Daklinza and ribavirin12 weeks